CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the "Company" or "CARMAT"), announces the success of its first "Aeson® European User Meeting", held on 21 and 22 November 2024 in Chantilly, near Paris.
The forum brought together more than 100 European leaders in cardiology (cardiologists, surgeons, anaesthetists, intensivists, nurses, specialized distributors, etc.), representing 41 hospitals and 10 countries (France, Germany, Italy, Spain, Poland, the Netherlands, Serbia, Slovenia, Macedonia and Israel), demonstrating an extremely strong interest from the medical community in the Aeson® artificial heart.
Following a summary of the clinical experience and results of Aeson® by Dr Piet Jansen, Medical Director of CARMAT, the different thematic sessions were led by a number of European physicians who have already used Aeson®, enabling them to share their experience with their peers (including those who have not yet implanted Aeson®).
Strong intent to use Aeson® among participants
Out of the 41 hospitals represented, around half of them had already performed at least one Aeson® implant, which provided a wealth of information to the twenty or so centers trained and present at the conference, which had not yet done so.
In this context, drawing on his experience of 7 Aeson® implants at the Lille University Hospital (France), Professor Vincentelli and Dr Moussa shared their approach and advice for a successful initiation and development of an Aeson® programme in a hospital, stressing in particular the need for close collaboration between all key stakeholders (hospital administration, cardiologists, surgeons, anaesthetists, nurses, etc).
When asked about their intent to carry-on or start implanting Aeson®, all the hospitals taking part in the meeting, confirmed that they were planning to implant the device in 2025, which paves the way for a strong growth in sales over the coming months.
Ultimate goal: Secure "destination therapy" status
Building on its growing and extremely encouraging experience in the bridge-to-transplant indication, CARMAT continues to ultimately aim for the "destination therapy" ("DT") indication, which would enable patients to live sustainably on Aeson® support without subsequent heart transplant. Destination therapy was mentioned several times by participants in the forum, as a natural and anticipated therapeutic development for Aeson®.
To this end, CARMAT confirms that it plans to resume its PIVOTAL study in Europe in the second half of 2025, on a cohort of patients not eligible for transplant.
Approval in "DT" would be a decisive step in meeting the critical challenge of graft shortage, given that only 5% of patients in need of a transplant can actually benefit from it. As such, the DT indication represents the largest addressable market opportunity in cardiology. CARMAT anticipates that securing this indication could take a few years.
Stéphane Piat, Chief Executive Officer of CARMAT, comments : "I'm delighted with the success of this first User Meeting organized by CARMAT. Over and above the high number of participants, which in itself, is exceptional, it is really the quality of the discussions and the enthusiasm and commitment of the healthcare professionals behind our Aeson® heart that make me very optimistic about the deployment of our artificial heart.
The experience shared by the physicians during the meeting confirms a real need for our therapy, a very wide range of patients who could benefit from Aeson®, and our high-quality clinical results. All this feedback leads me to believe that the number of implants is going to grow in centers already using Aeson®, and that many of the 30 or so trained hospitals, that have not yet carried out their first implant, will take the plunge in the near future.
Combined, our clinical results, state-of-the-art production facilities and strong support of the medical community, position us well to become the leader in the fast-growing advanced heart failure market.
I would like to thank all the participants in this conference, especially the physicians who have led the various workshops, and the CARMAT teams who have organized this event. More than ever, I believe that together, we can make Aeson® the reference treatment for advanced heart failure."
About CARMAT
CARMAT is a French MedTech that designs, manufactures and markets the Aeson® artificial heart. The Company’s ambition is to make Aeson® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world’s first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States. Founded in 2008, CARMAT is based in the Paris region, with its head offices located in Vélizy-Villacoublay and its production site in Bois-d’Arcy. The Company can rely on the talent and expertise of a multidisciplinary team of circa 200 highly specialized people. CARMAT is listed on the Euronext Growth market in Paris (Ticker: ALCAR / ISIN code: FR0010907956).
For more information, please go to www.carmatsa.com and follow us on LinkedIn.
Name: CARMAT
ISIN code: FR0010907956
Ticker: ALCAR
Disclaimer
This press release and the information it contains do not constitute an offer to sell or subscribe, or the solicitation of an order to buy or subscribe, CARMAT shares in any country.
This press release may contain forward-looking statements about the Company's objectives and prospects. These forward-looking statements are based on the current estimates and expectations of the Company's management and are subject to risk factors and uncertainties, including those described in its universal registration document filed with the Autorité des Marchés Financiers (AMF) under number D.24-0374, as updated by an amendment to the 2023 universal registration document filed with the AMF on 17 September 2024 under number D. 24-0374-A01 (together the ‘2023 Universal Registration Document’), and available on CARMAT's website.
Readers' attention is particularly drawn to the fact that the Company's current financing horizon is limited to the beginning of 2025 and that, given its financing requirements and the dilutive instruments in circulation, the Company's shareholders are likely to experience significant dilution of their stake in the Company in the short term. The Company is also subject to other risks and uncertainties, such as the Company's ability to implement its strategy, the pace of development of CARMAT's production and sales, the pace and results of ongoing or planned clinical trials, technological developments, changes in the competitive environment, regulatory developments, industrial risks and all risks associated with managing the Company's growth. The forward-looking statements contained in this press release may not be achieved as a result of these factors or other unknown risks and uncertainties or factors that the Company does not currently consider material and specific.
Aeson® is an active implantable medical device commercially available in the European Union and other countries recognising the CE mark. The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant in patients with end-stage biventricular heart failure (Intermacs classes 1-4) who cannot benefit from maximal medical therapy or a left ventricular assist device (LVAD) and who are likely to benefit from a heart transplant within 180 days of implantation. The decision to implant and the surgical procedure must be carried out by healthcare professionals trained by the manufacturer. The documentation (clinician's manual, patient's manual and alarm booklet) must be read carefully to learn about the characteristics of Aeson® and the information required for patient selection and proper use (contraindications, precautions, side effects) of Aeson®. In the United States, Aeson® is currently only available as part of a feasibility clinical trial approved by the Food & Drug Administration (FDA).
________________________________
1 ECMO = Extracorporeal membrane oxygenation
View source version on businesswire.com: https://www.businesswire.com/news/home/20241125445962/en/
Contacts
CARMAT
Stéphane Piat
Chief Executive Officer
Pascale d’Arbonneau
Chief Financial Officer
Tel.: +33 1 39 45 64 50
contact@carmatsas.com
Alize RP
Press Relations
Caroline Carmagnol
Tel.: +33 6 64 18 99 59
carmat@alizerp.com
NewCap
Financial Communication
& Investor Relations
Dusan Oresansky
Jérémy Digel
Tel.: +33 1 44 71 94 92
carmat@newcap.eu
